Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

63
Bank Stock Roundup: Robust Economic Data, Q2 Earnings, C, OZRK in Focus

2018-07-13 zacks
In the last five trading days, bank stocks delivered a bullish performance. While escalating trade war between the United States, China and the European Union continued to weigh on investor sentiments, strong economic data on the domestic front largely mitigated this. The latest job market data lessened the concern that the economy is in the late stage of expansion. This news resulted in rising yield on benchmark 10-year Treasury Notes.
WFCNP COF.PRG COF.PRH CMA.WS COF.WS WFC.PRL COF.PRP WFC.PRJ KEY FITBI SAM CMPWW BAC USB COF-D WFC.PRT COF-C COF-F WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY COF.PRC WFC.PRX COF.PRD WFC.PRW WFC.PRV COF.PRF BBT WFC WFC.WS BAC C COF-P CMA COF OZRK BLK FITB

6
Oppenheimer Positive on Banks Into Earnings: 4 to Buy Now

2018-07-13 247wallst
After a sparkling 2017, many of the top bank and financial institution stocks have sputtered in 2018, and with the economy improving and the prospects for interest rates to go higher, the sector may be offering investors some of the best opportunities. Another positive for the industry has been tax reform, which appears to be helping to improve credit quality, which is a huge metric for financial institutions as they are often the lenders of first choice for consumers.
COF.PRG COF.PRH COF-P SLMBP SLMAP COF.WS COF.PRP AXP COF SLM COF-D COF-C COF-F ALLY.PRA ALLY OSM COF.PRC COF.PRD ISM JSM COF.PRF

11
6 Most Important Things In Business Today

2018-07-13 247wallst
Commerce Secretary Wilbur Ross will sell all his equities after questions about conflicts of interest. According to Bloomberg:
COF.PRG COF.PRH COF-P COF.WS TWX COF.PRP COF TWC SYF WMT COF-D COF-C COF-F T AAPL COF.PRC DAL COF.PRD COF.PRF IVZ

4
PRESS DIGEST -Wall Street Journal - July 13

2018-07-13 reuters
July 13 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
COF.PRG COF.PRH FOX COF-P CCV CMCSA COF.WS TWX COF.PRP CCZ COF TWC COF-D COF-C NOC COF-F CCV.CL COF.PRC FOXA COF.PRD CMCSK COF.PRF

20
Walmart Weighs a Bid From Capital One for Credit Cards - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
COF.PRG COF.PRH C.WSA COF.WS COF.PRP COF-D COF-C C.WS.B COF-F C.WS.A C.PRP C.PRU COF.PRC COF.PRD COF.PRF C.PRS COF-P C C.PRL C.PRJ C.PRK COST COF C.PRG SYF C.PRC C.PRPCL CGBBW GPS

40
10 Billion-Dollar Stocks for Q3 and Beyond | InvestorPlace

2018-07-09 investorplace
Investment-related articles that generate the most hype frequently focus on speculative highfliers. While there’s always a time and place for that, especially if you’re in your twenties, a well-rounded portfolio should include well-capitalized industry stalwarts. These so-called billion-dollar stocks provide an extra level of confidence in uncertain times.
COF.PRG LMT RHI HD COF.PRH ABX COF-P XOM COF.WS COF.PRP COF RGR COF-D COF-C NOC SHW COF-F AMZN AAPL COF.PRC THC COF.PRD COF.PRF ABX

9
Top Analyst Upgrades and Downgrades: Baidu, Capital One, Delphi Technologies, Dunkin’ Brands, FireEye, Walgreens and More

2018-07-09 247wallst
The futures were again trading higher Monday morning. Despite concerns over the recently imposed tariffs around the world, investors and Wall Street have their attention focused on second-quarter earnings results, which will begin this week. The trend of buying the dips has not worked as well as it has in prior years, and many investors have been considering how they want their investments positioned for the longer term.
COF.PRG COF.PRH COF.WS MS.PRE COF.PRP MS.PRF MS.PRG MS.PRA DLPH COF-D COF-C COF-F FEYE MS COF.PRC BIDU COF.PRD HSY COF.PRF HSYFB COF-P COF MS.PRI BJ MS.PRK DNKN TRI

57
Bank Stock Roundup: Trade Issues Dent Investors' Confidence, WFC & Citi in Focus

2018-07-06 zacks
In the last four trading days, bank stocks put up a lackluster show. Mortgage rates declined in the week, hitting 4.52%, along with bond yields, on escalating trade issues between United States and its major trade allies. This weighed on investor sentiments. However, homeowners seeking lower rates for refinancing are turning out to be big-time gainers. Further, the benchmark 10-year Treasury yield shrunk this week as demand for safe-haven assets increased.
WFCNP COF.PRG COF.PRH RF.PRB RF.PRA FRC COF.WS WFC.PRL RF COF.PRP WFC.PRJ BAC USB COF-D FRC.PRA WFC.PRT COF-C COF-F WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN FRC.PRI FRC.PRH FRC.PRG FRC.PRF WFC.PRY 3772 WFC.PRX COF.PRC FRC.PRE COF.PRD FRC.PRD WFC.PRW FRC.PRC WFC.PRV COF.PRF FRC.PRB BBT WFC WFC.WS BAC C COF-P COF OZRK

46
Discover Financial to Return More Capital, Passes Stress Test

2018-07-02 zacks
Discover Financial Services (DFS - Free Report) recently announced that it has been notified by the Board of Governors of the Federal Reserve System that the regulatory body has no objections to the company’s capital actions through Jun 30, 2019. Per the company’s capital plan, it would increase its next quarterly dividend from 35 cents to 40 cents per share of common stock. During the four quarters ending Jun 30, 2019, it has also approved a share repurchase of up to $1.
COF.PRG HBANN COF.PRH HBANO DFS HBANP COF-P COF.WS COF.PRP COF HBAN COF-D DFS.PRB DFS.PRBCL COF-C COF-F COF.PRC COF.PRD COF.PRF

134
Top Analyst Upgrades and Downgrades: BlackRock, Capital One, Kroger, Nordstrom, Starbucks, Wells Fargo and More

2018-07-02 247wallst
The futures traded lower Monday morning as investors focused on the start of the third quarter. With earnings season ready to start in earnest next week, and the holiday-shortened week in place with the 4th of July celebration on Wednesday, it could be a very slow volume week for the indexes as trading is expected to be muted.
WFCNP COF.PRG COF.PRH STZ.B DB COF.WS WFC.PRL COF.PRP WFC.PRJ COF-D WFC.PRT COF-C COF-F WFC.PRR JWN WFC.PRQ KR WFC.PRP WFC.PRO WFC.PRN CAJ WFC.PRY WFC.PRX COF.PRC COF.PRD WFC.PRW WFC.PRV COF.PRF WFC WFC.WS COF-P COF STZ HHC BLK TRI SBUX

92
The Zacks Analyst Blog Highlights: Deutsche Bank, JPMorgan, Wells Fargo, Capital One and PNC

2018-07-02 zacks
Chicago, IL –July 2, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Deutsche Bank (DB - Free Report) , JPMorgan (JPM - Free Report) , Wells Fargo (WFC - Free Report) , Capital One Financial (COF) and PNC Financial (PNC - Free Report) .
WFCNP COF.PRG COF.PRH DB STT.PRC STT.PRE STT.PRD COF.WS STT.PRG MS.PRE WFC.PRL COF.PRP MS.PRF WFC.PRJ MS.PRG MS.PRA COF-D WFC.PRT COF-C COF-F WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY MS WFC.PRX COF.PRC COF.PRD WFC.PRW WFC.PRV COF.PRF WFC WFC.WS STT COF-P COF ISRG MS.PRI MS.PRK

157
Bank Stock Roundup: Trade War Fears, Capital Plan Approvals, JPM & WFC Dominate

2018-06-29 zacks
Over the last five trading days, bank stocks have put up a dismal performance as intensifying trade war fears continued to weigh on investor sentiments. Also, first-quarter 2018 GDP numbers were lowered after revision to 2% from 2.2% reported in May. Also, on Thursday, the Federal Reserve released results of its annual Comprehensive Capital Analysis and Review stress test. The central bank approved capital plans of 32 of 35 biggest banks in the United States.
WFCNP COF.PRG COF.PRH DB STT.PRC STT.PRE STT.PRD COF.WS STT.PRG MS.PRE WFC.PRL COF.PRP MS.PRF WFC.PRJ MS.PRG MS.PRA USB COF-D WFC.PRT COF-C COF-F WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY MS WFC.PRX COF.PRC PII COF.PRD WFC.PRW WFC.PRV COF.PRF WFC WFC.WS STT C COF-P COF MS.PRI MS.PRK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

5h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...